CONSIDER
• Why do physicians use urine drug monitoring with patients receiving opioid analgesics? • What are the normally expected metabolites of morphine?
• Had this patient on high-morphine therapy been abusing hydromorphone? • In the context of a hydromorphone-positive urine drug test in a patient administered only morphine, how might one distinguish between morphine adherence and unauthorized hydromorphone administration?
phone was first reported in 2006 by Cone et al., who performed a study in which hydromorphone was detected in 10 of 13 outpatients who had been prescribed morphine (hydromorphone:morphine ratio range 0.015-0.024) (4 ) . Recently, the same group again demonstrated this metabolic conversion in 34 of 34 outpatients administered unspecified "high-dose" morphine therapy (urine hydromorphone:morphine ratio range 0.002-0.020) (5 ) . In addition, Wasan et al. (6 ) recently reported data on a retrospective study involving 32 outpatients prescribed morphine therapy. These investigators tested urine specimens for hydromorphone by using GC-MS with a detection limit of 50 g/L. Of the 32 outpatients, 21 produced hydromorphone (urine hydromorphone:morphine ratio range 0.01-0.06) (Ajay Wasan, personal communication, October 17, 2008). In addition, the investigators tested solutions with morphine concentrations up to 25 000 g/L to determine whether hydromorphone could be formed during the chromatographic separation process. In these solutions, hydromorphone was not detected. Both groups, however, noted the provisional nature of their findings because of the possibility that urinary hydromorphone was attributable to unauthorized use of the opioid.
RESOLUTION OF CASE
This patient's opioid analgesic regimen was managed entirely-in both the hospice and hospital settings-by one of the authors (GMR). During at least the final 6 months of the patient's life she received no opioids other than morphine sulfate. She also was administered no known inhibitors or substrates of cytochrome P450 2D6 or UGT2B7. It should be noted that our patient required high-dose opioid analgesic therapy-in excess of 1500 mg/day of morphine. Although there is no "typical" morphine analgesic requirement, particularly in the context of end-of-life care, one study of hospice patients found that 90% were managed with Յ300 mg/ day of oral morphine equivalents (7 ) . Approximately 3 weeks before the patient's death, a urine specimen was collected from one of her bilateral nephrostomy tubes for determination of morphine and hydromorphone concentrations. The urine was collected in a standard specimen cup with no preservative, and was stored at 2-4°C before analysis. At the time the urine specimen was collected, serum indices of renal and hepatic function were within reference intervals.
An aliquot of the urine specimen was subjected to solid-phase extraction without enzymatic or acid hydrolysis, followed by GC-MS analysis. Morphine and hydromorphone were quantified by use of deuterated internal standards and a 5-point calibration curve. The mass spectrometer was operated in selected ionmonitoring mode, and identification of morphine and hydromorphone was based on ion ratios (8 ) . The morphine concentration in the urine specimen was Demethylation of codeine and its derivatives is catalyzed by the CYP2D6 enzyme. Heroin is sequentially deacetylated to morphine. It is first hydrolyzed to 6-acetylmorphine by serum cholinesterases, chiefly butyrylcholinesterase (BuChE), and subsequently hydrolyzed to morphine, chiefly by means of liver esterases. The enzymes responsible for conversion of morphine to hydromorphone, codeine to hydrocodone, and hydrocodone to dihydrocodeine are not known. About 75% of morphine is conjugated by the uridine-diphosphate glucuronyltransferase enzyme. Numbers in parentheses refer to the following references: 171 000 g/L, and the hydromorphone concentration was 104 g/L. The hydromorphone:morphine ratio was 0.0006. Dilution of the urine specimen (500ϫ) was required for the concentration of morphine to fall within the range of linearity. In this patient the possibility remained that the urinary hydromorphone was a contaminant in the pharmaceutical manufacture of the morphine sulfate rather than a product of the in vivo metabolic conversion of morphine to hydromorphone. To determine the purity of the drug being administered, tablets of MSContin ® (morphine sulfate, controlled release) and MSIR ® (morphine sulfate, immediate release) were dissolved in 0.9% saline, and we reextracted and analyzed the drug by using the same procedure as for the urine specimen. It should be noted that in the presence of very large amounts of morphine, as found in these pills, quantifying trace amounts of hydromorphone is difficult owing to chromatographic overload and its impact on analyte resolution and identification. The limit of detection for hydromorphone confirmed that the morphine sulfate immediate release (30-mg tablet) contained Ͻ0.0125 mg of hydromorphone, and the morphine sulfate controlled-release (100-mg tablet) contained Ͻ0.125 mg of hydromorphone. These maximum limits of hydromorphone contamination correspond to urine hydromorphone:morphine ratios of 0.00042 and 0.00125 for the immediate-and controlled-release formulations, respectively.
Although these findings do not eliminate the possibility that the hydromorphone in this patient's urine was due to contamination of the controlled-release morphine tablet, we believe this scenario to be unlikely for the following reasons: (a) we detected no hydromorphone in either the immediate-or controlledrelease morphine tablets, (b) we were unable to identify any published reports of hydromorphone contamination of pharmaceutical morphine preparations, and (c) the maximum possible hydromorphone:morphine ratio of 0.00125, although greater than the ratio found in our patient, was less than the ratio reported in all other published accounts, which comprise data from more than 60 individuals.
CONCLUSIONS
This case illustrates the appearance of hydromorphone as a minor metabolic product of morphine in the urine of a sequestered patient on chronic, high-dose morphine therapy with no access to hydromorphone. Our findings in this case confirm the findings of Cone et al. (4, 5 ) and Wasan et al. (6 ) In patients administered chronic morphine therapy, urine drug tests that yield morphine as well as small quantities of hydromorphone should be interpreted with caution, because the hydromorphone may be a morphine metabolic product rather than an indicator of unauthorized use of the opioid.
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POINTS TO REMEMBER
• Patients administered morphine may produce small amounts of hydromorphone, unlikely to exceed 6% of the urinary morphine concentration. Higher concentrations likely reflect hydromorphone administration.
• Similar metabolic conversions have been reported for other opioids, such as:
• codeine 3 morphine,
• codeine 3 hydrocodone (9 ),
• hydrocodone 3 hydromorphone,
• oxycodone 3 oxymorphone.
• Poppy seeds contain small amounts of opiates and may yield opiate-positive urine drug screen results and positive confirmations for morphine and codeine.
• Heroin (diacetylmorphine) is rapidly metabolized to 6-acetylmorphine and then to morphine. Morphine may be the only opioid detected in the urine of heroin abusers, although screening tests exist for 6-acetylmorphine, as well.
• Many physicians who order urine drug tests have insufficient understanding of opioid metabolism to correctly interpret urine drug testing results. Lack of awareness of opioid metabolic conversion may result in false accusations of opioid abuse.
Clinical Case Study
Clinical This case raises several interesting questions about the clinical role of urine drug testing. First, it is important to distinguish between clinical, patient-centered drug testing, which is done for the patient with informed consent, and regulated or forensic drug testing, which is rarely performed in the best interests of the patient. Clearly, the testing strategy is different in these 2 situations. This case discussion addresses the all too familiar challenges of end-of-life care that come to bear on the case of a young woman with end-stage cervical cancer. Although her case history is incomplete, it is clear that she had been on an escalating schedule of controlledand immediate-release morphine to control pain. The reason for conducting the drug test is unclear, however, and traces of hydromorphone in the urine sample appear to conflict with the palliative treatment plan in place.
The presence of unprescribed hydromorphone in the patient's urine may well have created some concern for her treatment team. The differential diagnosis that may account for such results includes medication error, interpatient medication diversion, and illicit drug smuggling by family or friends who believe they are assisting their dying loved one. Although the authors are likely correct in their interpretation of this finding as a minor metabolite of morphine, an occurrence first reported by Cone et al. in 2006 (1 ) , the authors also raise important questions about the ethical challenges of drug testing in general and testing at the end of life in particular.
Unfortunately, a lack of information about the patient's personal and family history precludes an assessment of risk of drug misuse and addiction. Even in the context of palliative care these issues remain important. A "universal precautions" approach to risk management may have answered many of these questions (2 ) . For example, a drug misuse history, particularly involving drugs in the opioid class, would have made the interpretation of the urine drug testing results more challenging. It is important to remember that drug misuse and addiction can and do occur in the palliative care setting, even in the relatively controlled context of a hospice. Although such behavior may pose ethical challenges regarding the use of controlled substances, even at the end of life, these issues are often overlooked.
Had the case involved chronic noncancer pain, this urine drug testing result might well have led to discontinuation of opioid medication at best or discharge of the patient from the practice, actions largely based on a failure to appreciate basic opioid metabolic pathways. The revelation that a minor metabolic pathway may have accounted for the presence of trace amounts of hydromorphone could be discerned only through a careful examination of the clinical context, thus illustrating the importance of a patient-centered, team approach to problem solving. We would encourage readers to approach urine drug testing in a patientcentered fashion (3 ).
